ReviewZeitschrift fur Rheumatologie2026
[Osteoporosis treatment in systemic sclerosis : Challenges and strategies in daily clinical practice].
Review in Zeitschrift fur Rheumatologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSystemic sclerosis (SSc) is a complex autoimmune disease with multiorgan involvement and substantial morbidity and mortality. As a result, patients with SSc are disproportionately affected by osteoporosis, which remains insufficiently characterized in the context of SSc and is often underrecognized in clinical practice.
objectiveTo present the current state of evidence regarding the epidemiology, pathophysiological mechanisms, diagnostic features, and therapeutic challenges of osteoporosis in the context of SSc.
methodsNarrative review of relevant primary and secondary literature (2003-2025) from PubMed, Embase, and current guideline sources, focusing on osteological aspects in SSc.
resultsPatients with SSc exhibit a significantly increased prevalence of osteoporosis and fractures. SSc aggravates osteoporosis risk factors such as postmenopausal status, malnutrition and low body weight through vasculopathy, fibrosis, as well as autoimmunity/inflammatory activity. The trabecular bone score (TBS) serves as a useful adjunct in fracture risk assessment. Furthermore, SSc complicates, especially due to gastrointestinal involvement, osteospecific therapy, with oral bisphosphonates appearing less effective. Preliminary evidence supports the effectiveness of parenteral antiresorptive agents.
conclusionOsteoporosis in SSc requires disease-specific risk assessment and an individualized diagnostic and therapeutic approach. Further prospective studies are needed to establish evidence-based treatment recommendations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.